Ji Woo Lee1, Hyung Jin Kim1, Yun Mee Choe2, Hee Suk Kang1, Soon Ki Kim1, Yong Hoon Jun1, Ji Eun Lee1. 1. Department of Pediatrics, Inha University Hospital, Grauduate School of Medicine, Inha University, Incheon, Korea. 2. Department of Surgery, Inha University Hospital, Grauduate School of Medicine, Inha University, Incheon, Korea.
Abstract
PURPOSE: Long-acting gonadotropin-releasing hormone agonists (GnRHa) are commonly used to treat central precocious puberty (CPP) in Korea. Although rare, there have been reports on the characteristic of adverse reactions of GnRHa in CPP among the Korean population. This study was intended to report on our clinical experience regarding significant adverse reactions to long-acting GnRHa in CPP and early onset puberty and to evaluate the prevalence rate of serious side effects. METHODS: This retrospective study included children with CPP and early onset puberty, who were administered monthly with long-acting GnRHa (leuprolide acetate, triptorelin acetate) at the outpatient clinic of Department of Pediatrics, at Inha University Hospital, between January 2011 and December 2013. We analyzed the clinical characteristics of patients who experienced significant adverse reactions and evaluated the prevalence rate. RESULTS: Six serious side effects (0.9%) were observed among total of 621 CPP and early onset puberty children with GnRHa therapy. The number of sterile abscess formation was four in three patients (4 events of 621). Anaphylaxis occurred in only one patient, and unilateral slipped capital femoral epiphysis (SCFE) in another one patient. Anaphylaxis occurred after the 6th administration of the monthly depot triptorelin acetate. Unilateral SCFE developed in GnRHa therapy. CONCLUSION: Sterile abscess formation occurred in 0.6% of CPP and early onset puberty patients from the administration of a monthly depot GnRHa therapy. The occurrences of anaphylaxis and SCFE are extremely rare, but can have serious implications on patients. Clinicians should be aware of these potential adverse effects related to GnRHa therapy in CPP.
PURPOSE: Long-acting gonadotropin-releasing hormone agonists (GnRHa) are commonly used to treat central precocious puberty (CPP) in Korea. Although rare, there have been reports on the characteristic of adverse reactions of GnRHa in CPP among the Korean population. This study was intended to report on our clinical experience regarding significant adverse reactions to long-acting GnRHa in CPP and early onset puberty and to evaluate the prevalence rate of serious side effects. METHODS: This retrospective study included children with CPP and early onset puberty, who were administered monthly with long-acting GnRHa (leuprolide acetate, triptorelin acetate) at the outpatient clinic of Department of Pediatrics, at Inha University Hospital, between January 2011 and December 2013. We analyzed the clinical characteristics of patients who experienced significant adverse reactions and evaluated the prevalence rate. RESULTS: Six serious side effects (0.9%) were observed among total of 621 CPP and early onset pubertychildren with GnRHa therapy. The number of sterile abscess formation was four in three patients (4 events of 621). Anaphylaxis occurred in only one patient, and unilateral slipped capital femoral epiphysis (SCFE) in another one patient. Anaphylaxis occurred after the 6th administration of the monthly depot triptorelin acetate. Unilateral SCFE developed in GnRHa therapy. CONCLUSION: Sterile abscess formation occurred in 0.6% of CPP and early onset pubertypatients from the administration of a monthly depot GnRHa therapy. The occurrences of anaphylaxis and SCFE are extremely rare, but can have serious implications on patients. Clinicians should be aware of these potential adverse effects related to GnRHa therapy in CPP.
Entities:
Keywords:
Central precocious puberty; Drug-related side effects and adverse reactions; Leuprolide; Triptorelin
Authors: Mark Inman; Brenden E Hursh; Arati Mokashi; Teresa Pinto; Daniel L Metzger; Elizabeth A Cummings Journal: Horm Res Paediatr Date: 2013-07-13 Impact factor: 2.852
Authors: Hugh A Sampson; Anne Muñoz-Furlong; Ronna L Campbell; N Franklin Adkinson; S Allan Bock; Amy Branum; Simon G A Brown; Carlos A Camargo; Rita Cydulka; Stephen J Galli; Jane Gidudu; Rebecca S Gruchalla; Allen D Harlor; David L Hepner; Lawrence M Lewis; Phillip L Lieberman; Dean D Metcalfe; Robert O'Connor; Antonella Muraro; Amanda Rudman; Cara Schmitt; Debra Scherrer; F Estelle R Simons; Stephen Thomas; Joseph P Wood; Wyatt W Decker Journal: J Allergy Clin Immunol Date: 2006-02 Impact factor: 10.793
Authors: Lieke Josephina Jeanne Johanna Vrouenraets; Annelou L C de Vries; Marijn Arnoldussen; Sabine E Hannema; Ramón J L Lindauer; Martine C de Vries; Irma M Hein Journal: Eur Child Adolesc Psychiatry Date: 2022-09-17 Impact factor: 5.349
Authors: Jadranka Popovic; Mitchell E Geffner; Alan D Rogol; Lawrence A Silverman; Paul B Kaplowitz; Nelly Mauras; Philip Zeitler; Erica A Eugster; Karen O Klein Journal: Front Pediatr Date: 2022-10-04 Impact factor: 3.569
Authors: Karen O Klein; Analía Freire; Mirta Graciela Gryngarten; Gad B Kletter; Matthew Benson; Bradley S Miller; Tala S Dajani; Erica A Eugster; Nelly Mauras Journal: J Clin Endocrinol Metab Date: 2020-10-01 Impact factor: 5.958